EDAP TMS S.A. Files 6-K, Signals Strategic Shift

Ticker: EDAP · Form: 6-K · Filed: Sep 9, 2025 · CIK: 1041934

Edap Tms SA 6-K Filing Summary
FieldDetail
CompanyEdap Tms SA (EDAP)
Form Type6-K
Filed DateSep 9, 2025
Risk Levellow
Pages9
Reading Time11 min
Key Dollar Amounts$5,084, $9,247, $12,992, $10,411, $763
Sentimentneutral

Sentiment: neutral

Topics: strategic-shift, foreign-private-issuer, ultrasound-technology

TL;DR

EDAP TMS S.A. is ditching old tech/distributors to become the undisputed leader in therapeutic ultrasound.

AI Summary

EDAP TMS S.A. filed a Form 6-K on September 9, 2025, reporting as a foreign private issuer. The filing indicates the company is transitioning from legacy technologies and a distributor model to become a global market leader in therapeutic ultrasound. The report is signed by Ken Mobeck, Chief Financial Officer.

Why It Matters

This filing signals a strategic pivot for EDAP TMS S.A., indicating a move away from older business models towards establishing dominance in the therapeutic ultrasound market.

Risk Assessment

Risk Level: low — This is a routine filing by a foreign private issuer and does not contain specific financial or operational news that would immediately impact risk.

Key Players & Entities

  • EDAP TMS S.A. (company) — Registrant
  • September 9, 2025 (date) — Filing Date
  • Ken Mobeck (person) — Chief Financial Officer

FAQ

What is the primary strategic shift EDAP TMS S.A. is undertaking?

EDAP TMS S.A. is shifting from legacy technologies and a distributor model to transform into the global market leader in therapeutic ultrasound.

What type of SEC filing is this?

This is a Form 6-K report of a foreign private issuer.

Who signed the report on behalf of EDAP TMS S.A.?

The report was signed by Ken Mobeck, Chief Financial Officer.

What is EDAP TMS S.A.'s fiscal year end?

EDAP TMS S.A.'s fiscal year ends on December 31.

What is EDAP TMS S.A.'s primary business classification?

EDAP TMS S.A. is classified under Standard Industrial Classification 3845: Electromedical & Electrotherapeutic Apparatus.

Filing Stats: 2,797 words · 11 min read · ~9 pages · Grade level 10.6 · Accepted 2025-09-09 07:00:09

Key Financial Figures

  • $5,084 — 2025 Site of Service CPT Code Procedure $5,084 (1) Standard OR 55875 Prostate Brachyth
  • $9,247 — tandard OR 55875 Prostate Brachytherapy $9,247 (1) Standard OR 55873 Cryo Ablation $12
  • $12,992 — 247 (1) Standard OR 55873 Cryo Ablation $12,992 (1) Specialized MRI Suite C9734 / 55882
  • $10,411 — ation $9,247 (1) Standard OR 55880 HIFU $10,411 (1) Standard OR 55866 Laparoscopic Pros
  • $763 — Work RVU (2025) (2) CPT Code Procedure $763 13.46 55875 Prostate Brachytherapy $744
  • $744 — $763 13.46 55875 Prostate Brachytherapy $744 13.60 55873 Cryo $579 11.50 55882 MRI T
  • $579 — ate Brachytherapy $744 13.60 55873 Cryo $579 11.50 55882 MRI Transurethral Ultrasoun
  • $951 — 2 MRI Transurethral Ultrasound Ablation $951 17.73 55880 HIFU $1,157 22.46 55866 Lap
  • $1,157 — trasound Ablation $951 17.73 55880 HIFU $1,157 22.46 55866 Laparoscopic Prostatectomy
  • $5.2M — ) (0.18) Earnings (Loss) Per Share HIFU $5.2M ESWL $2.5M Distribution $9.4M HIFU $9.7
  • $2.5M — rnings (Loss) Per Share HIFU $5.2M ESWL $2.5M Distribution $9.4M HIFU $9.7M +89% ESWL
  • $9.4M — hare HIFU $5.2M ESWL $2.5M Distribution $9.4M HIFU $9.7M +89% ESWL $1.8M - 27% 3 mont
  • $9.7M — 5.2M ESWL $2.5M Distribution $9.4M HIFU $9.7M +89% ESWL $1.8M - 27% 3 months 2024 3 m
  • $1.8M — Distribution $9.4M HIFU $9.7M +89% ESWL $1.8M - 27% 3 months 2024 3 months 2025 $ 1 7
  • $6.9M — 3 months 2025 $ 1 7 . 0 M Distribution $6.9M - 26% NOTE: Translated for convenience

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: September 9, 2025 EDAP TMS S.A. /s/ KEN MOBECK KEN MOBECK CHIEF FINANCIAL OFFICER The Global Leader in Therapeutic Ultrasound 1 Company Overview 3 Strategic Company Focus 4 Shift from Legacy Technologies and Distributor Model and Transform into the Global Market Leader in Robotic HIFU Focal Therapy Investment Thesis: Strong Growth Opportunity 5 x Large and Growing Market Opportunity: Urology and Prostate Cancer x Solves an Important Unmet Clinical Need in Cancer x Proven Compelling Clinical Evidence x Increasing Patient and Physician Demand x Strong Hospital and Physician Reimbursement x Leverages Current Advancements in Imaging, AI, and Robotics x Growing Worldwide Install Base x Ideally Positioned for Expanded Indications (BPH, Endometriosis, Other) 350+ Focal One Robotic HIFU Clinical Sites Large and Growing Market Opportunity In Urology and Prostate Cancer 7 3.3 Million American Men Living with Prostate Cancer in the U.S. (1) 313,780 New Cases Diagnosed in the U.S. (1) 35,770 U.S. Deaths from Prostate Cancer (1) U . S . P R O S T A T E C A N C E R M A R K E T Prostate Cancer is the Most Common Cancer Amongst Men In the U.S. Prostate (1) 2025 estimates from the American Cancer Society ( www.cancer.org ) 8 Lung & Bronchus Colorectum Skin Urinary Bladder New Cases Deaths Prostate Cancer Market Opportunity Number of New Prostate Cancer Cases Region 473,011 Europe 386,424 Asia 255,782 North America 225,985 Latin America 103,050 Africa 23,602 Oceania 1,467,854 Total L A R G E G L O B A L M A R K E T 1.5 Million New Prostate Cancer Cases Per Year 9 Data Source: Cases refers to Diagnosed Cases per year From World Health Organization – Globocan 2022 Focal One Answers an Unmet Need for a Large Underserved Pat

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.